Darin P Mcareavey
CIK 1365384 · View on SEC EDGAR ↗
First SEC filing: Jan. 15, 2014 · Latest: Jan. 15, 2014
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2012 | CREX | P | 1,700 | $0.67 | $1,139 | 28,700 Direct | +6.30% | Acquired | -99.1% (price as of 2026-08-20) |
| May 21, 2012 | CREX | P | 200 | $0.66 | $132 | 27,000 Direct | +0.75% | Acquired | -99.0% (price as of 2026-08-20) |
| May 21, 2012 | CREX | P | 100 | $0.67 | $67 | 26,800 Direct | +0.37% | Acquired | -99.1% (price as of 2026-08-20) |
| May 18, 2012 | CREX | P | 5,000 | $0.56 | $2,800 | 26,700 Direct | +23.04% | Acquired | -98.9% (price as of 2026-08-20) |
| Aug. 25, 2011 | CREX | P | 1,000 | $1.14 | $1,140 | 21,700 Direct | +4.83% | Acquired | -99.4% (price as of 2026-08-20) |
| May 18, 2011 | CREX | P | 1,900 | $1.31 | $2,489 | 20,700 Direct | +10.11% | Acquired | -99.5% (price as of 2026-08-20) |
| May 18, 2011 | CREX | P | 500 | $1.30 | $650 | 18,800 Direct | +2.73% | Acquired | -99.5% (price as of 2026-08-20) |
| May 18, 2011 | CREX | P | 1,600 | $1.28 | $2,048 | 18,300 Direct | +9.58% | Acquired | -99.5% (price as of 2026-08-20) |
| Nov. 5, 2010 | CREX | P | 1,000 | $1.39 | $1,390 | 16,700 Direct | +6.37% | Acquired | -99.5% (price as of 2026-08-20) |
| Nov. 4, 2010 | CREX | P | 290 | $1.41 | $409 | 15,700 Direct | +1.88% | Acquired | -99.6% (price as of 2026-08-20) |
| Nov. 4, 2010 | CREX | P | 1,390 | $1.43 | $1,988 | 15,410 Direct | +9.91% | Acquired | -99.6% (price as of 2026-08-20) |
| Nov. 4, 2010 | CREX | P | 320 | $1.45 | $464 | 14,020 Direct | +2.34% | Acquired | -99.6% (price as of 2026-08-20) |
| June 3, 2010 | CREX | P | 700 | $1.27 | $889 | 13,700 Direct | +5.38% | Acquired | -99.5% (price as of 2026-08-20) |
| June 3, 2010 | CREX | P | 600 | $1.26 | $756 | 13,000 Direct | +4.84% | Acquired | -99.5% (price as of 2026-08-20) |
| June 3, 2010 | CREX | P | 2,400 | $1.26 | $3,024 | 12,400 Direct | +24.00% | Acquired | -99.5% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 14, 2014 | CREX | Stock Option (right to buy) [F2] | Common Stock (50,000) | $0.79 | Jan. 14, 2024 | 50,000 | Acquired |
| Feb. 13, 2013 | CREX | Stock Option (right to buy) [F2] | Common Stock (25,000) | $1.80 | Feb. 13, 2023 | 25,000 | Acquired |
| Feb. 16, 2012 | CREX | Stock Option (right to buy) [F2] | Common Stock (50,000) | $1.07 | Feb. 16, 2022 | 50,000 | Acquired |
| June 9, 2011 | CREX | Stock Option (right to buy) [F2] | Common Stock (16,450) | $1.17 | March 23, 2021 | 16,450 | Acquired |
| March 23, 2011 | CREX | Stock Option (right to buy) [F2] | Common Stock (33,550) | $1.17 | March 23, 2021 | 33,550 | Acquired |
| March 17, 2010 | CREX | Stock Option (right to buy) [F3] | Common Stock (50,000) | $2.45 | March 17, 2020 | 50,000 | Acquired |
| March 9, 2009 | CREX | Stock Option (right to buy) [F1] | Common Stock (100,000) | $1.12 | March 9, 2019 | 100,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2012 | $215,000 | $0 | — | — | $0 | — | $400 | $249,332 |
| 2011 | $215,000,192,500 | $0 | — | — | $0 | — | $417,443 | $252,646,300,712 |
| 2009 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.